AbbVie (ABBV) to Release Earnings on Wednesday

AbbVie (NYSE:ABBV) is projected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect AbbVie to post earnings of $3.37 per share and revenue of $16.3913 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $3.00 EPS. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Trading Up 1.2%

Shares of ABBV stock opened at $225.76 on Tuesday. The firm has a fifty day moving average price of $224.33 and a 200 day moving average price of $218.90. The company has a market cap of $399.01 billion, a P/E ratio of 171.03, a PEG ratio of 0.92 and a beta of 0.35. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ABBV shares. Morgan Stanley upped their price objective on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research note on Tuesday, November 4th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. increased their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.17.

Institutional Trading of AbbVie

A number of large investors have recently bought and sold shares of ABBV. Quarry LP acquired a new position in AbbVie in the third quarter valued at $41,000. Rakuten Securities Inc. increased its position in AbbVie by 26.5% in the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock valued at $68,000 after acquiring an additional 77 shares during the period. Binnacle Investments Inc increased its position in AbbVie by 33.2% in the 2nd quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock valued at $92,000 after acquiring an additional 123 shares during the period. Triumph Capital Management purchased a new stake in AbbVie during the 3rd quarter valued at approximately $193,000. Finally, Wealth Watch Advisors INC acquired a new stake in AbbVie during the 3rd quarter worth approximately $210,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.